Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network …
H Wang, C Song, X Zhao, W Deng, J Dong… - Frontiers in …, 2023 - frontiersin.org
Objective This systematic review and meta-analysis aimed to investigate the role of
neoadjuvant immunochemotherapy with or without radiotherapy [NIC (R) T] compared to …
neoadjuvant immunochemotherapy with or without radiotherapy [NIC (R) T] compared to …
Efficacy and safety of PD-1 Monoclonal antibodies in the treatment of esophageal squamous cell carcinoma: Systematic review and meta Regression
Background Esophageal Squamous Cell Carcinoma (ESCC) contributes to the global
burden of disease. Conventional treatments such as surgical resection and chemotherapy …
burden of disease. Conventional treatments such as surgical resection and chemotherapy …
18F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
S Wang, S Di, J Lu, S Xie, Z Yu, Y Liang… - Thoracic Cancer, 2023 - Wiley Online Library
Background This study aimed to investigate the predictive value of 18F‐FDG PET/CT for
pathological response after neoadjuvant immunochemotherapy (NICT) in patients with …
pathological response after neoadjuvant immunochemotherapy (NICT) in patients with …
Efficacy and safety of pembrolizumab combined with albumin-bound paclitaxel and nedaplatin for advanced esophageal squamous cell carcinoma
F Yan, L Chen, M Ying, J Li, Q Fu - Immunotherapy, 2024 - Taylor & Francis
Objective: This research aimed to assess the efficacy and safety of pembrolizumab (PBL)
combined with albumin-bound paclitaxel (ab-Pac) and nedaplatin (NDP) for advanced …
combined with albumin-bound paclitaxel (ab-Pac) and nedaplatin (NDP) for advanced …
Study on the efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy regimen for III–IVA esophageal squamous cell carcinoma post-surgery
C Li, P Yu, H Li, X Yang, J Wang, B Jiang - Journal of Cardiothoracic …, 2024 - Springer
Background and aims The treatment of esophageal squamous cell carcinoma is still
controversial, and neoadjuvant chemotherapy combined with immunotherapy is a hot topic …
controversial, and neoadjuvant chemotherapy combined with immunotherapy is a hot topic …
Impact of Body Composition on Clinical Outcomes in Patients with Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Plus …
Y Zhao, M Xia, Y Dang, Y Li, X Zhao… - Annali Italiani di …, 2024 - annaliitalianidichirurgia.it
AIM: Some studies have reported that body composition profiles affect clinical outcomes of
multidisciplinary treatments in several types of cancers; however, a paucity of data exists on …
multidisciplinary treatments in several types of cancers; however, a paucity of data exists on …
Responses to commentary on 'Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: a systematic review and meta-analysis' …
Z Wang, Y Wang, Y Feng, X Yan - International Journal of Surgery, 2023 - journals.lww.com
It is a great honor that our study 'Efficacy and safety of neoadjuvant immunotherapy in
surgically resectable esophageal cancer: a systematic review and meta-analysis' published …
surgically resectable esophageal cancer: a systematic review and meta-analysis' published …